AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 142 min read$ODTX

Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply

Odyssey Therapeutics (ODTX) reported Q2 2026 results with $433.1M cash, enough for operations into 2028. The company is advancing its lead drug OD-001, with Phase 2a data expected in October and two new trials planned. Net loss widened to $52.8M due to increased R&D spending. The company has no product revenue yet.

Original reporting
yahoo.com
Published Sep 14, 2026, 3:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply — source image
Source · yahoo.com
Decision brief

The 30-second read

$ODTXNeutralMed
01

Why it matters

The Q2 earnings and trial expansion provide fresh data points for valuation models, but the lack of near‑term efficacy data keeps price action muted.

02

Market read

Quarterly results and pipeline updates are material for investors in the biotech space, offering a basis for position adjustments.

03

What to watch

Potential dilution risk if additional capital is needed before trial readouts.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Odyssey Therapeutics is a clinical‑stage biotech focused on autoimmune diseases, with its lead RIPK2 inhibitor OD-001 in Phase 2 trials.

Company-level read

Ticker impact

$ODTXNeutralMedium confidence
Context

Odyssey Therapeutics reported Q2 results with $433.1M cash and announced two new clinical trials, providing fresh financial and pipeline data.

Expected impact

Potential modest upside if trial data are positive; downside risk from cash burn.

Evidence & confidence

New cash balance and trial plans are material for a biotech, but no near‑term data releases limit immediate price move.

Market effects

Sector

Adds to the pipeline momentum narrative in the autoimmune biotech sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

The cash runway may be insufficient if trial failures occur, leading to a sharper sell‑off.

Key entities

  • Company
    Odyssey Therapeutics

    Clinical‑stage biopharma developing autoimmune therapies.

  • Executive
    Gary D. Glick

    CEO of Odyssey Therapeutics, quoted on trial milestones.

Read at source← All news

Related articles

SEP 5
$ODTXHighAI 8/10

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.

stocktwits.com2 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
AUG 6
$EVOMed

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.

prnewswire.com2 min
AUG 4
$ODTXMed

Odyssey Therapeutics, Inc. (ODTX): Results of Operations and Financial Condition

Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedoliz

SEC EDGAR 8-K2 min
JUN 17
$ODTXLow

Odyssey Therapeutics, Inc. (ODTX): Results of Operations and Financial Condition

Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001882782 0001882782 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

SEC EDGAR 8-K2 min